

Survey: **DS4/25**
month: **November 2025**
Participant-No: **9907016**
valid from: **08.11.25**

Krajská nemocnice T. Bati, a.s.
Oddeleni klinické biochemie
a farmakologie
Prim. MUDr. Tomáš Sálek, Ph.D., EuSpLM
Havlickovo nábřeží 600
76275 ZLIN
CZECH REPUBLIC

Bonn, 19. December 2025

Participation certificate

We confirm that you have participated in the survey for drug screening.
Your findings and the corresponding ratings were the following:

(• = correct, f = false, ? = missing, # = false positive)

I. Screening (immunologic)

	Sample A		Sample B	
	findings	rating	findings	rating
- Amphetamine group	+	•	-	•
- Barbiturates	+	•	-	•
- Benzodiazepines	-	•	-	•
- Cannabinoids	+	•	-	•
- Cocain + metabolites	+	•	-	•
- Methadon + metabolites	-	•	+	•
- Opiates	-	•	+	•
- Tricycl. antidepressants	+	•	-	•
- Methamphetamin	+	•	-	•



Prof. Dr. C. Knabbe
EQA scheme director



Dr. Anja Kessler
Head of Reference Institute



Dr. Stefanie Gemein
EQAS-Board